Saturday, 6 January 2018

Research on Brain Mapping


Various experiments have been Conducted among the scientists to map the connections in the brain this is called as 'connectome’ and to understand how it relates to human behaviour, such as intelligence and mental disorders.
Research published in the journal Neuron, Scientists of the University of Cambridge and the National Institutes of Health (NIH), USA, has shown that it is possible to build up a map of the connectome by analysing regular brain scans taken by magnetic resonance imaging (MRI) scanner.
The group compared the brains of 296 typically adolescent volunteers. These results were certified in a cohort of a further 124 volunteers. The group used conventional 3T MRI scanner, i.e. where 3T represents the strength of magnetic field. Cambridge has recently install a much more powerful Siemens 7T Terra MRI scanner, which should allow the technique to give an even more precise mapping to the human brain.
MRI scan will be providing a one image of the brain from which, it is possible to calculate the multiple structural features of the brain. The scientists must show, that if two regions have similar profiles and have 'morphometric similarity'.
Morphometric similarity network, the scientists must generate a map showing the connection between every neuron to neuron. Scientists found a link among the connectivity channel.

"What makes some brains more connected than to others, as it is down to their genetics or their educational upbringing, i.e., how do these connections strengthen or weaken across development?"


Thursday, 28 December 2017

25th International Conference on Neurochemistry and Neuropharmacology

Stem cells from schizophrenics produce fewer neurons


Stem cells obtained from patients with schizophrenia carry a genetic mutation that alters the ratio of the different type of nerve cells they produce, according to a new study by researchers in Japan.
non-neuronal cells are generated during the earliest stages of brain development.Schizophrenia is a debilitating mental illness that affects about 1 in 100 people. It is known to be highly heritable, but is genetically complex: so far, researchers have identified over 100 rare genetic variations and dozens of mutations associated with increased risk of developing the disease. One of the best characterised mutations associated with the disease is a microdeletion on chromosome 22, within a region containing dozens of genes known to be involved in the development, maturation, and function of brain circuits. This deletion is found in 1 in every 2,000 – 4,000 live births; all patients carrying it exhibit various psychiatric symptoms and conditions, with just under a third of them developing schizophrenia in adolescence or early adulthood.

Brain’s immune cells hyperactive in schizophrenia

Some Brain Science Institutes  and their  colleagues obtained skin cells from two female schizophrenic patients diagnosed with the chromosome 22 deletion and two healthy individuals, then reprogrammed them to generate induced pluripotent stem cells (iPSCs), unspecialised cells which, like embryonic stem cells, retain the ability to differentiate into all the different cell types in the body. They then compared the properties of iPSCs obtained from the schizophrenic patients with those from the healthy controls.
First, the researchers ‘plated’ the cells onto Petri dishes and treated them with chemicals so that they began to differentiate into neural stem cells. Under these conditions, iPSCs aggregate spontaneously to form ‘neurospheres’. These free-floating spherical clusters contain neural stem cells, which can differentiate further into any type of nerve cell, and also some neural progenitors, or immature nerve cells that have started to differentiate into neurons or glia, the non-neuronal cell types in the nervous system.
They immediately noticed that the neurospheres derived from iPSCs obtained from the schizophrenic patients were significantly smaller than those formed from iPSCs from the two healthy controls.
On closer inspection, they found other abnormalities. They treated the neurospheres with fluorescent antibodies that bind specifically to proteins synthesized only by neurons or glial cells called astrocytes, and looked at them under the microscope.

Monday, 25 December 2017

Electrical Brain Stimulation in Treatment of Neurodegenerative Diseases : 25th International Conference on Neurochemistry and Neuropharmacology


The early Egyptians and Romans recognized the numbing effect of the electric properties of catfish. In fact, Romans were the first to cultivate electric fishes for pain relieving effect. But since then, not much has changed in the development of electricity based medical treatments. Things only started to change two millennia later with the discovery of electricity and a better understanding of neurophysiology.
Electroconvulsive therapy was born in the middle of the 19th century. In the early days, it was primarily used to treat neuropsychiatric disorders. In the mid-19th century, direct electric current was used for electroconvulsive therapy. By the end of 19th-century, the alternate current was discovered, and its use along with the use of magnetic fields became the subject of experiments not only investigating neuropsychiatric conditions but also other diseases like epilepsy and chronic severe headaches.
Electroconvulsive therapy is still used in the treatment of severe neuropsychiatric conditions like schizophrenia or depression, where suicidal tendencies do not respond to pharmacological agents. Unlike in the old days, now this is a non-invasive treatment usually performed under general anesthesia. The therapy non-selectively resets various centers in the brain and thus has wide-ranging side effects like loss of memory, headaches, and muscle aches.
Considering the widespread side effects of electroconvulsive therapy, the need for more selective stimulation of particular brain centers specific for a particular disease was obvious. The improvements in understanding of brain physiology and surgical techniques gave rise to “deep brain stimulation” (DBS). This is an invasive method where electrodes are surgically placed inside the specific part of the brain that are connected to a small electrical device that generates the stimulation.
At present, DBS has been shown to be effective in the treatment of Parkinson’s disease, epilepsy, obsessive compulsive disorder, and dystonia. It is being studied for applications in treating depression, drug addiction, and other neurodegenerative disorders such as dementia. As the method is invasive and involves the surgical implantation of electrodes inside the brain, it is reserved for cases that fail to respond to pharmacological therapy.
The upcoming “25th International Conference on Neurochemistry & Neuropharmacology “which is being held on 17th and 18th September 2018 at Dubai, UAE. Neurochemistry Congress 2018 is expected to give in-vogue research phase to Neurologists, enlisted and diverse pros and understudies working in the field to consider, exchange views and their experiences before an extensive worldwide social occasion of individuals. The social gathering welcomes Presidents, CEO's, Delegates and present-day authorities from the field of Neurology, Nursing, Healthcare, and other relevant administration positions to participate in these sessions, B2B get together and board talks.
For more : https://neurochemistry.neurologyconference.com/

Thursday, 30 November 2017

NEUROCHEMISTRY CONGRESS 2018

ConferenceSeries Ltd is a renowned organization that organizes highly notable pharmaceutical, Chemistry and other Life Sciences conferences throughout the globe. ConferenceSeries Ltd organizes 600+ Conferences every year across USA, Europe & Asia with support from 1000 more scientific societies and publishes 700+ Open access journals which contain over 70000 eminent personalities, reputed scientists as editorial board members, 1200 Symposium & Workshops and 5 million followers.

Neurochemistry Congress 2018 invites all the participants from all over the world to attend 25th International Conference on Neurochemistry and Neuropharmacology during September 17-18, 2018 in Dubai, UAE. which includes prompt keynote presentations, Oral talks, Poster presentations, Workshops and Exhibitions.

Why to attend???

With members from around the world focused on learning about neuropharmacology and its advances; this is your best opportunity to reach the largest assemblage of participants from the Neurochemistry & Neuropharmacology community conduct presentations, distribute information, meet with current and potential scientists, make a splash with new drug developments, and receive name recognition at this 2-day event. World-renowned speakers, the most recent techniques, developments, and the newest updates in Neurochemistry & Neuropharmacology are hallmarks of this conference.

Target Audience:


  • Neurochemistry Students
  • Neurochemistry Scientists
  • Neurochemistry Researchers
  • Neurochemistry  Faculty
  • Medical Colleges
  • Neurochemistry Associations and Societies
  • Manufacturing Medical Devices Companies
  • Neuropharmacology Students
  • Neuropharmacology Scientists
  • Neuropharmacology Researchers
  • Neuropharmacology Faculty
  • Medical Colleges
  • Neuropharmacology Associations and Societies
  • Business Entrepreneurs
  • Training Institutes


2018 Highlights:


  • 300+ Participation (70 Industry: 30 Academia)
  • 5+ Keynote Speakers
  • 50+ Plenary Speakers
  • 20+ Exhibitors
  • 14 Innovative Educational Sessions
  • 5+ Workshops
  • B2B Meetings

Conference Highlights